\u8a73\u7d30\u306f\u3053\u3061\u3089<\/a><\/p>","protected":false},"excerpt":{"rendered":"TOKYO, Japan, 31 May 2023: \u2013 PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced a milestone achievement of a clinical development conducted by Ohara Pharmaceutical Co., Ltd., a Japanese pharmaceutical company that discovers and develops orphan drugs and generic drugs, based on their licensing […]<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","tags":[],"news-category":[8],"class_list":["post-1775","news","type-news","status-publish","hentry","news-category-news","post"],"yoast_head":"\n
PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical - PRISM BioLab<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/prismbiolab.com\/ja\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/\" \/>\n<meta property=\"og:locale\" content=\"ja_JP\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical - PRISM BioLab\" \/>\n<meta property=\"og:description\" content=\"TOKYO, Japan, 31 May 2023: \u2013 PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced a milestone achievement of a clinical development conducted by Ohara Pharmaceutical Co., Ltd., a Japanese pharmaceutical company that discovers and develops orphan drugs and generic drugs, based on their licensing […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/prismbiolab.com\/ja\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/\" \/>\n<meta property=\"og:site_name\" content=\"PRISM BioLab\" \/>\n<meta property=\"article:modified_time\" content=\"2023-05-31T12:47:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/prismbiolab.com\/wp-content\/uploads\/2024\/07\/career-collage.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1122\" \/>\n\t<meta property=\"og:image:height\" content=\"1097\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\\\/\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\\\/\",\"name\":\"PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical - PRISM BioLab\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#website\"},\"datePublished\":\"2023-05-31T06:00:41+00:00\",\"dateModified\":\"2023-05-31T12:47:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\\\/#breadcrumb\"},\"inLanguage\":\"ja\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/prismbiolab.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"News\",\"item\":\"https:\\\/\\\/prismbiolab.com\\\/news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#website\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/\",\"name\":\"PRISM BioLab\",\"description\":\"PRISM BioLab MIMICS natural peptides leading to cures of the greatest health challenges\",\"publisher\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/prismbiolab.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"ja\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#organization\",\"name\":\"PRISM BioLab\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ja\",\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/prismbiolab.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/prism_logo_b.jpg\",\"contentUrl\":\"https:\\\/\\\/prismbiolab.com\\\/wp-content\\\/uploads\\\/2021\\\/09\\\/prism_logo_b.jpg\",\"width\":300,\"height\":367,\"caption\":\"PRISM BioLab\"},\"image\":{\"@id\":\"https:\\\/\\\/prismbiolab.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical - PRISM BioLab","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/prismbiolab.com\/ja\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/","og_locale":"ja_JP","og_type":"article","og_title":"PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical - PRISM BioLab","og_description":"TOKYO, Japan, 31 May 2023: \u2013 PRISM BioLab, a Japan based biotechnology company with a proprietary peptide mimetic small molecule drug discovery platform, today announced a milestone achievement of a clinical development conducted by Ohara Pharmaceutical Co., Ltd., a Japanese pharmaceutical company that discovers and develops orphan drugs and generic drugs, based on their licensing […]","og_url":"https:\/\/prismbiolab.com\/ja\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/","og_site_name":"PRISM BioLab","article_modified_time":"2023-05-31T12:47:46+00:00","og_image":[{"width":1122,"height":1097,"url":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2024\/07\/career-collage.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/prismbiolab.com\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/","url":"https:\/\/prismbiolab.com\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/","name":"PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical - PRISM BioLab","isPartOf":{"@id":"https:\/\/prismbiolab.com\/#website"},"datePublished":"2023-05-31T06:00:41+00:00","dateModified":"2023-05-31T12:47:46+00:00","breadcrumb":{"@id":"https:\/\/prismbiolab.com\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/#breadcrumb"},"inLanguage":"ja","potentialAction":[{"@type":"ReadAction","target":["https:\/\/prismbiolab.com\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/prismbiolab.com\/news\/prism-biolab-announces-a-milestone-achievement-based-on-the-license-agreement-with-ohara-pharmaceutical\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/prismbiolab.com\/"},{"@type":"ListItem","position":2,"name":"News","item":"https:\/\/prismbiolab.com\/news\/"},{"@type":"ListItem","position":3,"name":"PRISM BioLab announces a milestone achievement based on the license agreement with Ohara Pharmaceutical"}]},{"@type":"WebSite","@id":"https:\/\/prismbiolab.com\/#website","url":"https:\/\/prismbiolab.com\/","name":"PRISM BioLab","description":"PRISM BioLab MIMICS natural peptides leading to cures of the greatest health challenges","publisher":{"@id":"https:\/\/prismbiolab.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/prismbiolab.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"ja"},{"@type":"Organization","@id":"https:\/\/prismbiolab.com\/#organization","name":"PRISM BioLab","url":"https:\/\/prismbiolab.com\/","logo":{"@type":"ImageObject","inLanguage":"ja","@id":"https:\/\/prismbiolab.com\/#\/schema\/logo\/image\/","url":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2021\/09\/prism_logo_b.jpg","contentUrl":"https:\/\/prismbiolab.com\/wp-content\/uploads\/2021\/09\/prism_logo_b.jpg","width":300,"height":367,"caption":"PRISM BioLab"},"image":{"@id":"https:\/\/prismbiolab.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/1775","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news"}],"about":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/types\/news"}],"author":[{"embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/comments?post=1775"}],"version-history":[{"count":5,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/1775\/revisions"}],"predecessor-version":[{"id":1788,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news\/1775\/revisions\/1788"}],"wp:attachment":[{"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/media?parent=1775"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/tags?post=1775"},{"taxonomy":"news-category","embeddable":true,"href":"https:\/\/prismbiolab.com\/ja\/wp-json\/wp\/v2\/news-category?post=1775"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}